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Etanercept plus methotrexate in psoriasis
This study evaluated etanercept monotherapy vs. etanercept 
plus methotrexate in patients with moderate-to-severe plaque 
psoriasis. Patients received etanercept 50 mg twice weekly 
for 12 weeks followed by 50 mg once weekly for 12 weeks 
and were randomized 1 : 1 to receive methotrexate (7.5–15 
mg weekly) or placebo; 239 patients were enrolled in each 
arm. PASI 75 was significantly higher at week 24 for the 
combination therapy group compared with the monotherapy 
group (77.3% vs. 60.3%; P < 0.0001). Adverse events were 
reported in 74.9% and 59.8% of combination therapy and 
monotherapy groups, respectively. It is concluded that etan-
ercept plus methotrexate may be a viable regimen in patients 
with psoriasis. Br J Dermatol 2012; 167:675–83.
Tofacitinib improves the clinical signs  
of psoriasis
Tofacitinib is a novel, oral Janus kinase inhibitor. This Phase 
2b study was designed to assess the efficacy and safety of 
three twice-daily oral tofacitinib regimens vs. placebo, in 
patients with moderate-to-severe chronic plaque psoriasis. 
At week 12, PASI 75 response rates were significantly higher 
for all tofacitinib twice-daily. The most frequently reported 
adverse events (AEs) were infections and infestations: 22.4% 
(2 mg twice daily), 20.4% (5 mg twice daily), 36.7% (15 mg 
twice daily) and 32.0% (placebo). Changes from baseline in 
haemoglobin and neutrophils were small, dose related and 
not progressive. Dose-related increases in serum cholesterol 
were noted. It is concluded that short-term treatment with 
oral tofacitinib results in significant clinical improvement 
in patients with moderate-to-severe plaque psoriasis. Br J 
Dermatol 2012; 167:694–703.
Prior corticosteroid exposure and the clinical 
course in SJS/TEN
This is a case–control study based on data collected in the 
EuroSCAR and RegiSCAR studies. Ninety-two cases of 
Stevens–Johnson syndrome (SJS) and toxic epidermal necrol-
ysis (TEN) with exposure to corticosteroids prior to the onset 
of disease, and 321 randomly selected patients with SJS/TEN 
without prior exposure were included. On multivariate anal-
ysis, cases with prior exposure to corticosteroids had a lon-
ger progression of disease by 2.2 days. The disease severity 
and mortality outcome were unaffected. In addition, there is 
evidence that corticosteroids delayed the onset of SJS/TEN in 
patients with exposure to high-risk drugs by 7.1 days. These 
findings suggest that corticosteroids have a mild impact on 
the course of SJS/TEN, and further studies are required to 
clarify any potential therapeutic effects. Br J Dermatol 2012; 
167:587–94.
Rosacea in the U.K.
Using the U.K.-based General Practice Research Database, 
Spoendlin et al. identified patients with an incident diagnosis 
of rosacea between 1995 and 2009 and matched them (1 : 1) 
to rosacea-free control patients. The overall incidence rate 
for rosacea diagnosed in the U.K. was 1.65 per 1000 person-
years. Rosacea was diagnosed in some 80% of cases after the 
age of 30 years. Ocular symptoms were recorded in 20.8% 
of cases at the index date. There was a significantly reduced 
relative risk of developing rosacea among current smokers 
and a marginal increased risk with alcohol consumption. Br J 
Dermatol 2012; 167:630–37.
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